Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus

Diabetic Medicine

Volumn 14, Issue 6, 1997, Pages 423-432

  Carter, A M ^a   Grant, P J ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Adhesion molecules; Endothelial cells; Leukocytes; Macrovascular disease; Platelets

Indexed keywords

BETA THROMBOGLOBULIN; CELL ADHESION MOLECULE; HEMOSTATIC AGENT; IMMUNOGLOBULIN; INTEGRIN; SELECTIN; THROMBOCYTE FACTOR 4; VASOACTIVE AGENT;

ATHEROSCLEROSIS; BLOOD CLOTTING; CELL INTERACTION; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR DISEASE;

BLOOD VESSELS; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HOMEOSTASIS; HUMANS; MALE; VASCULAR DISEASES;

EID: 0030749545     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199706)14:6<423::AID-DIA421>3.0.CO;2-F     Document Type: Review

References (42)

1. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987; 36: 689-692.
2. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79-84.
3. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13.
4. Koistinen MJ, Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. Br Med J 1990; 301: 92-95.
5. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacological Reviews 1994; 46: 325-415.
6. Chabrier PE. The role of endothelin in the vessel wall. Baillières Clin Haematol 1993; 6: 577-591.
7. Suzuki M, Ohyama Y, Satoh S. Conversion of angiotensin I to angiotensin II and inactivation of bradykinin in canine peripheral vascular beds. J Cardiovasc Pharmacol 1984; 6: 244-250.
8. Simonson MS, Dunn MJ. Cellular signaling by peptides of the endothelin gene family. FASEB J 1990; 4: 2989-3000.
9. Davies MG, Hagen PO. The vascular endothelium. A new horizon. Annals of Surgery 1993; 218: 593-609.
10. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC, Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
11. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
12. lgnarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical, Circ Res 1987; 61: 866-879.
13. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
14. Cohen RA. The role of nitric oxide and other endothel iumderived vasoactive substances in vascular disease. Prog Cardiovas Dis 1995; 38: 105-128.
15. Davies PF, Tripathi SC. Mechanical stress mechanisms and the cell. An endothelial paradigm. Circ Res 1993; 72: 239-245.
16. Loskove JA, Frishman WH. Nitric oxide donors in the treatment of cardiovascular and pulmonary diseases. Am Heart J 1995; 129: 604-613.
17. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: role of nitric oxide. Journal of Cellular Physiology 1994; 158: 485-494.
18. Prins BA, Hu RM, Nazario B, Pedram A, Frank HJ, Weber MA, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938-11944.
19. Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991; 18 (suppl III): 115-121.
20. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annual Review of Medicine 1996; 47: 315-331.
21. Pearson JD. Endothelial cell function and thrombosis. Baillières Clin Haematol 1994; 7: 441-452.
22. Meyer D, Girma JP. von Willebrand factor: structure and function. Thromb Haemost 1993; 70: 99-104.
23. Badimon L, Badimon JJ, Chesebro JH, Fuster V. von Willebrand factor and cardiovascular disease. Thromb Haemost 1993; 70: 111-118.
24. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
25. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in athero-sclerosis. Thrombosis & Haemostasis 1995; 74: 626-630.
26. Catto AJ, Carter AM, Barrett JH, Boothby M, Bamford J, Grant PJ. Elevated von Willebrand factor (vWF): an independent risk factor for cerebrovascular mortality. (Abstract) Blood Coagul Fibrinolysis 1995; 6: 590.
27. Fay PJ. Factor VIII structure and function. Thromb Haemost 1993; 70: 63-67.
28. Fitzgerald DJ. Platelet activation in the pathogenesis of unstable angina: importance in determining the response to plasminogen activators. Am J Cardiol 1991; 68: 51B-57B.
29. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-1601.
30. Peerschke EI. Stabilization of platelet-fibrinogen interactions is an integral property of the glycoprotein IIb-IIIa complex. J Lab Clin Med 1994; 124: 439-446.
31. Bini A, Kudryk BJ. Fibrinogen in human atherosclerosis. Ann NY Acad Sci 1995; 748: 461-471.
32. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender specific associations of the fibrinogen Bb 448 polymor-phism, fibrinogen levels and acute cerebrovascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 589-594.
33. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.
34. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo JC. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men, Arter Thromb 1994; 14: 54-59.
35. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
36. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250.
37. Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-791.
38. Chapman PT, Haskard DO. Leukocyte adhesion molecules. Br Med Bull 1995; 51: 296-311.
39. McEver RP. Role of selectins in leukocyte adhesion to platelets and endothelium. Ann NY Acad Sci 1994; 714: 185-189.
40. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
41. Ikeda H, Takajo Y, Ichiki K, Ueno T, Maki S, Noda T, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92: 1693-1696.
42. Eppihimer MJ, Wolitzky B, Anderson DC, Labow MA,